Evidence map›Paper›PMID 36077643›Full record

ArticleCancers2022

Correlation between BAP1 Localization, Driver Mutations, and Patient Survival in Uveal Melanoma.

Yasemin C Cole, Yu-Zhi Zhang, Beatrice Gallo, Adam P Januszewski, Anca Nastase, David J Essex, Caroline M H Thaung, Victoria M L Cohen, Mandeep S Sagoo, Anne M Bowcock

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Impact of Spliceosome Inhibition in SF3B1-Mutated Uveal Melanoma.Investigative ophthalmology & visual science · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yasemin C ColeNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.ORCID 0000-0002-9492-5885
Yu-Zhi ZhangNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.ORCID 0000-0002-6134-980X
Beatrice GalloOcular Oncology Service, Moorfields Eye Hospital & St. Bartholomew's Hospital, London EC1V 2PD, UK.
Adam P JanuszewskiNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.
Anca NastaseNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.
David J EssexOcular Oncology Service, Moorfields Eye Hospital & St. Bartholomew's Hospital, London EC1V 2PD, UK.
Caroline M H ThaungMoorfields Eye Hospital, London EC1V 2PD, UK.ORCID 0000-0002-8318-046X
Victoria M L CohenOcular Oncology Service, Moorfields Eye Hospital & St. Bartholomew's Hospital, London EC1V 2PD, UK.ORCID 0000-0002-7793-160X
Mandeep S SagooOcular Oncology Service, Moorfields Eye Hospital & St. Bartholomew's Hospital, London EC1V 2PD, UK.ORCID 0000-0003-1530-3824
Anne M BowcockNational Heart and Lung Institute, Imperial College London, London SW3 6LR, UK.ORCID 0000-0001-8691-9090
Imperial College London · GBSt Bartholomew's Hospital · GBMoorfields Eye Hospital NHS Foundation Trust · GBRoyal Brompton & Harefield NHS Foundation Trust · GB

Funding

THE GENETICS OF OCULAR MELANOMAR01CA161870 · NCI · WASHINGTON UNIVERSITY · PI BOWCOCK, ANNE MARY · 2011 to 2024
$5.5M
National Heart and Lung Institute's National Centre for Mesothelioma Research NANCI NIH HHS R01 CA161870NCI NIH HHS R01CA161870
6 · The paper itself

Abstract

Uveal melanoma (UM) is an uncommon but highly aggressive ocular malignancy. Poor overall survival is associated with deleterious BAP1 alterations, which frequently occur with monosomy 3 (LOH3) and a characteristic gene expression profile. Tumor DNA from a cohort of 100 UM patients from Moorfields Biobank (UK) that had undergone enucleation were sequenced for known UM driver genes (BAP1, SF3B1, EIF1AX, GNAQ, and GNA11). Immunohistochemical staining of BAP1 and interphase FISH for chromosomes 3 and 8 was performed, and cellular localization of BAP1 was correlated with BAP1 mutations. Wildtype (WT) BAP1 staining was characterized by nBAP1 expression with <10% cytoplasmic BAP1 (cBAP1). Tumors exhibited heterogeneity with respect to BAP1 staining with different percentages of nBAP1 loss: ≥25% loss of nuclear BAP1 (nBAP1) was superior to chr8q and LOH3 as a prognostic indicator. Of the successfully sequenced UMs, 38% harbored oncogenic mutations in GNA11 and 48% harbored mutations in GNAQ at residues 209 or 183. Of the secondary drivers, 39% of mutations were in BAP1, 11% were in EIF1AX, and 20% were in the SF3B1 R625 hotspot. Most tumors with SF3B1 or EIF1AX mutations retained nuclear BAP1 (nBAP1). The majority of tumor samples with likely pathogenic BAP1 mutations, regardless of mutation class, displayed ≥25% loss of nBAP1. This included all tumors with truncating mutations and 80% of tumors with missense mutations. In addition, 60% of tumors with truncating mutations and 82% of tumors with missense mutations expressed >10% cBAP1.

Indexed as

BAP1biomarkersEIF1AXimmunohistochemistrymetastasismonosomy 3nonsense-mediated decaySF3B1survivaluveal melanoma

Identifiers

PMID36077643
PMCPMC9454448
OpenAlexW4293103591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.